Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Probosciseson Apr 05, 2023 2:47pm
291 Views
Post# 35381594

The Importance of Surrounding Oneself with Competent People

The Importance of Surrounding Oneself with Competent PeopleMatt has said in recent podcasts that his goal as CEO is to not hire anyone stupider than him.  He wants qualified and capable people in key roles.  He seems to be doing a decent job of selecting good people and then effectively delegating to them.  Could the selection of effective people like Heinenam, de Guttadauro, and others be a contributing factor to the methodical success of ONC/Y since 2017?  Matt also speaks highly of the bright minds in pharma, academia (like Richard Vile), and the FDA.  While this is a good interpersonal tactic it is also true that engaging the brightest and the best is also the best path forward for a company.  Unfortumately, some insecure leaders are reluctant to surround themselves with smarter folk, but Matt seems to welcome and encourage excellence.  Lately, I've been impressed by both Heineman and de Guttadauro.  They don't strike me as mere ornaments while Matt is calling the shots.  They are providing capable leadership in their respective roles.  I think the mis-impression by some that Matt is calling all the shots to bolster his own ego is incorrect.  I believe the same is true as regards any deal that might happen.  IMO Matt is not the cork in the bottle that will supress any reasonable deal. There is a capable C-suite and board that will collectively determine the future path of ONC/Y.    


<< Previous
Bullboard Posts
Next >>